Welcome to our dedicated page for Adaptimmune Therapeutics news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics stock.
Adaptimmune Therapeutics plc reports corporate and business developments for its ADSs and engineered T-cell therapy operations in solid tumor cancers. News has covered financial results, TECELRA commercial updates, cell therapy asset transactions, debt repayment, restructuring activity, and remaining programs directed at PRAME and CD70.
Company updates also address Nasdaq listing matters, ADS trading status, deregistration actions, executive changes, and conference participation. Adaptimmune’s disclosed business context centers on its engineered T-cell receptor platform, personalized cell therapies, and the corporate transition following the completed transfer of TECELRA, lete-cel, afami-cel, and uza-cel assets.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) has priced an underwritten public offering of 20.5 million American Depositary Shares (ADSs) at $11.00 each, aiming for a gross size of $225.5 million. The offering will support the advancement of Adaptimmune’s immunotherapy development and general corporate purposes. Underwriters have a 30-day option to purchase an additional 3.075 million ADSs. The offering is expected to close around June 4, 2020, pending customary conditions. Cowen and SVB Leerink are jointly managing the offering.
Adaptimmune Therapeutics (Nasdaq: ADAP) reported significant developments in its latest press release. The company received a $50 million upfront payment from Astellas and completed an offering generating approximately $90 million. Financial guidance confirmed that funds will last into 2H 2021. The EU granted Orphan Drug Designation for ADP-A2M4, enhancing its position alongside existing US designations. Upcoming presentations scheduled for major scientific meetings will showcase data on ADP-A2M4 and other programs. The company's net loss for Q1 2020 was $28.2 million.
Adaptimmune Therapeutics (Nasdaq: ADAP) presented significant advancements in its allogeneic T-cell therapy platform at the ASGCT Annual meeting. The company has successfully engineered T-cells from human induced pluripotent stem cells (hiPSCs) that can target and kill MAGE-A4+ cancer cells in vitro. A milestone was achieved with the editing of T-cell receptor expression into hiPSCs' genome, which is crucial for creating large banks of functional T-cells. These developments mark essential progress toward potential clinical applications of Adaptimmune's proprietary therapies.
Summary not available.